Skip to Main Content

Paper Details

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Breast Cancer Res
24
2012
BrCa, CHK1, DNA repair/, RRM1 and 2, Ribonucleotide, Ribonucleotide reductase 1 and 2, TNBC, TNBC cell, TNBC cells, Tag, Tag gene signature, Tag signature, Triple-negative breast cancer, breast cancer, cell cycle gene signature, checkpoint kinase 1, gemcitabine, human, human breast cancer cell lines, patients, proliferation/, ribonucleotide, ribonucleotide reductase, triple-negative breast cancer, tumor, up-regulated genes

Datasets

Release 1.2